EKF Diagnostics Holdings plc
("EKF" or the "Company")
Director's Share Options
EKF Diagnostics Holdings plc (AIM: EKF), the growing in-vitro diagnostics company, announces that the Company has agreed to a 6 month extension of the exercise period relating to share options over 500,000 Ordinary Shares previously granted to Gordon Hall, Non-Executive Director of the Company, in 2005.
The latest date for the exercise of these options has been extended by 6 months from 28 June 2012 to 28 December 2012. The exercise price remains unchanged at 20 pence per Ordinary Share.
Enquiries:
|
EKF Diagnostics Holdings plc |
Tel: 029 2071 0570 |
|
|
David Evans, Executive Chairman |
||
|
Julian Baines, CEO |
||
|
Canaccord Genuity Limited |
Tel: 020 7523 8000 |
|
|
Jamie Adams / Mark Dickenson / Lucy Tilley |
||
|
Walbrook PR Limited |
Tel: 020 7933 8780 |
|
|
Paul McManus |
Mob: 07980 541 893 or paul.mcmanus@walbrookpr.com |
|
This information is provided by RNS